287 related articles for article (PubMed ID: 25963524)
1. ARID1A and TERT promoter mutations in dedifferentiated meningioma.
Abedalthagafi MS; Bi WL; Merrill PH; Gibson WJ; Rose MF; Du Z; Francis JM; Du R; Dunn IF; Ligon AH; Beroukhim R; Santagata S
Cancer Genet; 2015 Jun; 208(6):345-50. PubMed ID: 25963524
[TBL] [Abstract][Full Text] [Related]
2. SWI/SNF chromatin remodeling complex alterations in meningioma.
Gill CM; Loewenstern J; Rutland JW; Arib H; Pain M; Umphlett M; Kinoshita Y; McBride RB; Bederson J; Donovan M; Sebra R; Fowkes M; Shrivastava RK
J Cancer Res Clin Oncol; 2021 Nov; 147(11):3431-3440. PubMed ID: 33715086
[TBL] [Abstract][Full Text] [Related]
3. TERT promoter mutations in primary and secondary WHO grade III meningioma.
Maier AD; Stenman A; Svahn F; Mirian C; Bartek J; Juhler M; Zedenius J; Broholm H; Mathiesen T
Brain Pathol; 2021 Jan; 31(1):61-69. PubMed ID: 32805769
[TBL] [Abstract][Full Text] [Related]
4. TERT Promoter Mutations and Risk of Recurrence in Meningioma.
Sahm F; Schrimpf D; Olar A; Koelsche C; Reuss D; Bissel J; Kratz A; Capper D; Schefzyk S; Hielscher T; Wang Q; Sulman EP; Adeberg S; Koch A; Okuducu AF; Brehmer S; Schittenhelm J; Becker A; Brokinkel B; Schmidt M; Ull T; Gousias K; Kessler AF; Lamszus K; Debus J; Mawrin C; Kim YJ; Simon M; Ketter R; Paulus W; Aldape KD; Herold-Mende C; von Deimling A
J Natl Cancer Inst; 2016 May; 108(5):. PubMed ID: 26668184
[TBL] [Abstract][Full Text] [Related]
5. Distinct genomic subclasses of high-grade/progressive meningiomas: NF2-associated, NF2-exclusive, and NF2-agnostic.
Williams EA; Santagata S; Wakimoto H; Shankar GM; Barker FG; Sharaf R; Reddy A; Spear P; Alexander BM; Ross JS; Brastianos PK; Cahill DP; Ramkissoon SH; Juratli TA
Acta Neuropathol Commun; 2020 Oct; 8(1):171. PubMed ID: 33087175
[TBL] [Abstract][Full Text] [Related]
6. TERT promoter mutation is associated with worse prognosis in WHO grade II and III meningiomas.
Biczok A; Kraus T; Suchorska B; Terpolilli NA; Thorsteinsdottir J; Giese A; Tonn JC; Schichor C
J Neurooncol; 2018 Sep; 139(3):671-678. PubMed ID: 29808339
[TBL] [Abstract][Full Text] [Related]
7. TERT promoter mutations are associated with poor prognosis and cell immortalization in meningioma.
Spiegl-Kreinecker S; Lötsch D; Neumayer K; Kastler L; Gojo J; Pirker C; Pichler J; Weis S; Kumar R; Webersinke G; Gruber A; Berger W
Neuro Oncol; 2018 Nov; 20(12):1584-1593. PubMed ID: 30010853
[TBL] [Abstract][Full Text] [Related]
8. De novo and secondary anaplastic meningiomas: a study of clinical and histomolecular prognostic factors.
Peyre M; Gauchotte G; Giry M; Froehlich S; Pallud J; Graillon T; Bielle F; Cazals-Hatem D; Varlet P; Figarella-Branger D; Loiseau H; Kalamarides M
Neuro Oncol; 2018 Jul; 20(8):1113-1121. PubMed ID: 29216385
[TBL] [Abstract][Full Text] [Related]
9. High incidence of activating TERT promoter mutations in meningiomas undergoing malignant progression.
Goutagny S; Nault JC; Mallet M; Henin D; Rossi JZ; Kalamarides M
Brain Pathol; 2014 Mar; 24(2):184-9. PubMed ID: 24261697
[TBL] [Abstract][Full Text] [Related]
10. Mutational Analysis of Recurrent Meningioma Progressing From Atypical to Rhabdoid Subtype.
Bujko M; Machnicki MM; Grecka E; Rusetska N; Matyja E; Kober P; Mandat T; Rydzanicz M; Płoski R; Krajewski R; Bonicki W; Stokłosa T; Siedlecki JA
World Neurosurg; 2017 Jan; 97():754.e1-754.e6. PubMed ID: 27756662
[TBL] [Abstract][Full Text] [Related]
11. Genetic alterations associated with progression and recurrence in meningiomas.
Pérez-Magán E; Campos-Martín Y; Mur P; Fiaño C; Ribalta T; García JF; Rey JA; Rodríguez de Lope A; Mollejo M; Meléndez B
J Neuropathol Exp Neurol; 2012 Oct; 71(10):882-93. PubMed ID: 22964784
[TBL] [Abstract][Full Text] [Related]
12. Anaplastic meningioma: progression from atypical and chordoid morphotype with morphologic spectral variation at recurrence.
Bollag RJ; Vender JR; Sharma S
Neuropathology; 2010 Jun; 30(3):279-87. PubMed ID: 19780983
[TBL] [Abstract][Full Text] [Related]
13. Comparative genomic hybridization analysis of genomic alterations in benign, atypical and anaplastic meningiomas.
Arslantas A; Artan S; Oner U; Durmaz R; Müslümanoğlu H; Atasoy MA; Başaran N; Tel E
Acta Neurol Belg; 2002 Jun; 102(2):53-62. PubMed ID: 12161900
[TBL] [Abstract][Full Text] [Related]
14. Intratumoral patterns of clonal evolution in meningiomas as defined by multicolor interphase fluorescence in situ hybridization (FISH): is there a relationship between histopathologically benign and atypical/anaplastic lesions?
Sayagués JM; Tabernero MD; Maíllo A; Espinosa A; Rasillo A; Díaz P; Ciudad J; López A; Merino M; Gonçalves JM; Santos-Briz A; Morales F; Orfao A
J Mol Diagn; 2004 Nov; 6(4):316-25. PubMed ID: 15507670
[TBL] [Abstract][Full Text] [Related]
15. Malignant progression to anaplastic meningioma: Neuropathology, molecular pathology, and experimental models.
Cimino PJ
Exp Mol Pathol; 2015 Oct; 99(2):354-9. PubMed ID: 26302177
[TBL] [Abstract][Full Text] [Related]
16. Telomerase activity and expression of the telomerase catalytic subunit, hTERT, in meningioma progression.
Simon M; Park TW; Leuenroth S; Hans VH; Löning T; Schramm J
J Neurosurg; 2000 May; 92(5):832-40. PubMed ID: 10794298
[TBL] [Abstract][Full Text] [Related]
17. Prognostic value of allelic losses and telomerase activity in meningiomas.
Leuraud P; Dezamis E; Aguirre-Cruz L; Taillibert S; Lejeune J; Robin E; Mokhtari K; Boch AL; Cornu P; Delattre JY; Sanson M
J Neurosurg; 2004 Feb; 100(2):303-9. PubMed ID: 15098535
[TBL] [Abstract][Full Text] [Related]
18. Poor prognosis associated with TERT gene alterations in meningioma is independent of the WHO classification: an individual patient data meta-analysis.
Mirian C; Duun-Henriksen AK; Juratli T; Sahm F; Spiegl-Kreinecker S; Peyre M; Biczok A; Tonn JC; Goutagny S; Bertero L; Maier AD; Møller Pedersen M; Law I; Broholm H; Cahill DP; Brastianos P; Poulsgaard L; Fugleholm K; Ziebell M; Munch T; Mathiesen T
J Neurol Neurosurg Psychiatry; 2020 Apr; 91(4):378-387. PubMed ID: 32041819
[TBL] [Abstract][Full Text] [Related]
19. Diagnostic and prognostic significance of genetic regional heterogeneity in meningiomas.
Pfisterer WK; Hank NC; Preul MC; Hendricks WP; Pueschel J; Coons SW; Scheck AC
Neuro Oncol; 2004 Oct; 6(4):290-9. PubMed ID: 15494096
[TBL] [Abstract][Full Text] [Related]
20. DNA methylation-based classification and grading system for meningioma: a multicentre, retrospective analysis.
Sahm F; Schrimpf D; Stichel D; Jones DTW; Hielscher T; Schefzyk S; Okonechnikov K; Koelsche C; Reuss DE; Capper D; Sturm D; Wirsching HG; Berghoff AS; Baumgarten P; Kratz A; Huang K; Wefers AK; Hovestadt V; Sill M; Ellis HP; Kurian KM; Okuducu AF; Jungk C; Drueschler K; Schick M; Bewerunge-Hudler M; Mawrin C; Seiz-Rosenhagen M; Ketter R; Simon M; Westphal M; Lamszus K; Becker A; Koch A; Schittenhelm J; Rushing EJ; Collins VP; Brehmer S; Chavez L; Platten M; Hänggi D; Unterberg A; Paulus W; Wick W; Pfister SM; Mittelbronn M; Preusser M; Herold-Mende C; Weller M; von Deimling A
Lancet Oncol; 2017 May; 18(5):682-694. PubMed ID: 28314689
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
